Citigroup analyst, Joel Beatty, reiterated his Buy on shares of Syndax Pharmaceuticals (NASDAQ: SNDX) and raised his PT to $24 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE